FOR IMMEDIATE RELEASE - Innophos

Summary Cash Flow StatementINNOPHOS HOLDINGS, INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows (Unaudited)(Dollars in thousands)Year endedYear endedDecember 31, December 31,2011 2010Cash flows from operating activitiesNet income $86,522 $45,155Adjustments to reconcile net income to net cash provided from operating activities:Depreciation and amortization 43,676 49,471Amortization of deferred financing charges 608 7,150Deferred income tax provision 5,379 (6,680)Deferred profit sharing (286) (2,064)Share-based compensation 6,250 5,090Changes in assets and liabilities:Decrease in restricted cash - 1,749Increase in accounts receivable (28,154) (18,346)Increase in inventories (45,021) (9,546)Decrease (increase) in other current assets 3,238 (34,270)(Decrease) increase in accounts payable (5,939) 16,716(Decrease) increase in other current liabilities (14,685) 24,522Changes in other long-term assets and liabilities (5,242) (2,989)Net cash provided from operating activities 46,346 75,958Cash flows from investing activities:Capital expenditures (34,195) (31,192)Investment in Kelatron (20,533) -Net cash used for investing activities (54,728) (31,192)Cash flows from financing activities:Proceeds from exercise of stock options 484 236Long-term debt borrowings 3,000 170,000Long-term debt repayments - (267,000)Deferred financing costs - (2,828)Excess tax benefits from exercise of stock options 2,511 640Common stock repurchases (6,156) -Dividends paid (19,921) (14,559)Net cash used for financing activities (20,082) (113,511)Net change in cash (28,464) (68,745)Cash and cash equivalents at beginning of period 63,706 132,451Cash and cash equivalents at end of period $35,242 $63,706Note: 2011 includes 2 months of Kelatron